Finance

Lists
FAE:BME
FAES Farma SA
€ 4.80
+1.05%
(+0.050) 1D
10-р сарын 9, 09:00:22 (GMT+2)  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FAE...
Open
€ 4.80
High
€ 4.80
Low
€ 4.80
Mkt. cap
1.52 тэрбум
Avg. vol.
188.70 мян
Volume
48.00
Dividend
2.67%
Quarterly dividend
€ 0.03
Ex-dividend date
2026 оны 7-р сарын 2
P/E ratio
17.85
52-wk high
€ 5.44
52-wk low
€ 4.32
EPS
€ 0.27
Shares outstanding
316.22 сая
No. of employees
3 мян
Open
€ 4.80
High
€ 4.80
Low
€ 4.80
Mkt. cap
1.52 тэрбум
Avg. vol.
188.70 мян
Volume
48.00
Dividend
2.67%
Quarterly dividend
€ 0.03
Ex-dividend date
2026 оны 7-р сарын 2
P/E ratio
17.85
52-wk high
€ 5.44
52-wk low
€ 4.32
EPS
€ 0.27
Shares outstanding
316.22 сая
No. of employees
3 мян
News stories
From web sources and news partners
pharmaphorum
pharmaphorum
·
18 минутын өмнө
Iambic prices its IPO, seeking to raise up to $160m
Simply Wall Street
Simply Wall Street
·
9 минутын өмнө
Meta (META) Now Has Two New Problems In Teens And AI
Profile
Faes Farma, originally Fábrica Española de Productos Químicos y Farmacéuticos, is a Spanish pharmaceutical company based in the Lamiaco district of Lejona in Biscay. Founded on 29 July 1933 by the Serra family with an initial capital of two million pesetas, it pioneered the development of various therapeutic compounds and has been listed on the Madrid Stock Exchange since the 1940s. Faes Farma’s headquarters, production facilities, and R&D center are located in Lejona, with additional offices in Madrid and Barcelona. The group also operates subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Bolivia, Ecuador and Nigeria, and maintains an animal nutrition and health division under the name FARM Faes. Wikipedia
About FAES Farma SA
CEO-
Employees2.61 мян
Founded1933 оны 7-р сарын 29
Headquarters-
SectorPharmaceutical industry
Last report
2026 оны 7-р сарын 30
Fiscal period
Q2 2026
€ 0.09 / -
0.00%miss
Revenue / Est. (EUR)
401.85 сая / 189.65 сая
+111.89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
146.61 сая
172.99 сая
200.07 сая
191.39 сая
Cost of goods sold
52.40 сая
73.44 сая
61.59 сая
60.25 сая
Cost of revenue
52.40 сая
73.44 сая
61.59 сая
60.25 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.36 сая
80.84 сая
45.67 сая
44.06 сая
Operating expense
68.06 сая
98.44 сая
100.13 сая
98.54 сая
Total operating expenses
120.47 сая
171.88 сая
161.72 сая
158.78 сая
Operating income
26.14 сая
1.11 сая
38.35 сая
32.61 сая
Other non operating income
401.00 мян
1.02 сая
-
-
EBT including unusual items
25.18 сая
-1.39 сая
36.36 сая
30.47 сая
EBT excluding unusual items
25.18 сая
-1.65 сая
36.36 сая
30.47 сая
Income tax expense
3.75 сая
-7.43 сая
5.49 сая
4.32 сая
Effective tax rate
14.91%
534.46%
15.10%
14.19%
Other operating expenses
33.65 сая
7.21 сая
44.62 сая
44.44 сая
Net income
21.23 сая
6.07 сая
30.79 сая
26.10 сая
Net profit margin
14.48%
3.51%
15.39%
13.64%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
1.41 сая
Interest expense
-1.99 сая
-3.51 сая
-1.99 сая
-3.58 сая
Net interest expenses
-1.99 сая
-3.51 сая
-1.99 сая
-2.18 сая
Depreciation and amortization charges
7.05 сая
10.39 сая
9.83 сая
10.04 сая
EBITDA
30.15 сая
6.94 сая
44.19 сая
40.50 сая
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс